Find Clinical Trials

Inclusion Criteria for mBC: * Diagnosed for having breast cancer at least in stage 3B or confirm to have metastatic breast cancer * Live at home * Considered as adult (Eighteen years of age or older) Exclusion Criteria for mBC: \- mBC patients will be exclude when their physical condition is deteriorating or when they need hospitalization. The following criteria will be applied for family caregivers: 1. Appointed by mBC patients or self-identified as family caregiver of mBC patients for at least 3 months 2. Live/not live together with mBC patients but providing care to mBC patient 3. Considered as adult (Eighteen years of age or older) Inclusion criteria for cadre: The local cadre in Yogyakarta and Bali who self-identified as local cadre in the community and willing to involve for assisting mBC patients. The local cadre will be excluded when they are not providing consent to involve in the current study.

Inclusion Criteria: * Adult outpatients (18-75 years old) with unipolar depression experiencing major depressive episodes as determined by the DSM5 and characterized as MDD-TRD (diagnosed with major depressive disorder as outlined by the DSM5) and experienced at least two previous failed antidepressant treatments of adequate dose and duration for the current episode Exclusion Criteria: * Individuals with psychosis, main diagnosis of personality disorder, uncontrolled hypertension, substance abuse, currently pregnant or breastfeeding, or who had a previous negative reaction to ketamine or esketamine, were ineligible to receive IV ketamine or IN esketamine.

Inclusion Criteria: * Living with type 2 diabetes mellitus Exclusion Criteria: * Have a significant cognitive impairment, * Are non-ambulatory, * Have lower extremity amputation, * Have renal failure, * Have liver disease, * Have uncontrolled hypertension (\>160 mmHg systolic and/or \>100 mmHg diastolic), * Have unstable cardiovascular disease, * Have a history of severe cardiovascular problems, * Have decompensated heart failure, * Have uncontrolled arrhythmias, * Have severe pulmonary hypertension (mean pulmonary arterial pressure \>55 mm Hg), * Have severe and symptomatic aortic stenosis, * Have acute myocarditis, endocarditis, or pericarditis, * Have aortic dissection, * Have Marfan syndrome, * Have unrepaired aortic aneurysm, * Have proliferative diabetic retinopathy, * Have rapidly progressive terminal illness, * Are unable to perform resistance exercise to due preexisting musculoskeletal conditions (e.g., joint pain, chronic injury or tendinopathy), * Are under biguanide (metformin) treatment, but are taking for less than 3 months, * Have taken drugs known to increase the risk of tendon disorders (e.g., tendinopathy and tendon rupture) within the last 6 months. These drugs include, but may not be limited to: fluoroquinolones, glucocorticoids, aromatase inhibitors, anabolic steroids, antiretrovirals, isotretinoin, cephalexin, rituximab, sitagliptin, cephalosporins, azithromycin, and sulfonamides. * Are pregnant or trying to become pregnant during the study, * Are prisoners, * Are persons that require a legally authorized representative. Temporary exclusions include: * Being subjected to recent surgeries for which resistance training is not recommended, * Have symptomatic hernias, * Have acute illness, * Have recent fractures, or other injuries until resolved.

Inclusion Criteria: 1. Adults 18 to 65 years old; 2. Must be deemed to have capacity to provide informed consent; 3. Must sign and date the informed consent form; 4. Stated willingness to comply with all study procedures; 5. Ability to read and communicate in English, such that their literacy and comprehension is sufficient for understanding the consent form and study questionnaires, as evaluated by study staff obtaining consent; 6. Primary DSM-5 diagnosis of non-psychotic MDD, single or recurrent, based on the Structured Clinical Interview for DSM-5 (SCID-5) administered at the first screening visit; 7. Participants diagnosed with treatment-resistant depression defined as individuals with a baseline HamD-17 score \> 14 and that have not responded to two or more separate trials of antidepressants at an adequate dosage and duration (an antidepressant resistance rating score of three or more is considered an adequate trial) based on the Antidepressant Treatment History Form (ATHF); there is no upper limit on the number of treatment failures; 8. Ability to take oral medication; 9. Individuals who are capable of becoming pregnant: use of highly effective contraception for at least 3 months prior to screening and agreement to use such a method during study participation; 10. Individuals who are willing to taper off current antidepressant and antipsychotic medications for a minimum of 2-weeks (or more depending on the medication) prior to Baseline (V2) and whose physician confirms that it is safe for them to do so; and 11. Agreement to adhere to Lifestyle Considerations (section 4.5) throughout study duration. Exclusion Criteria: 1. Pregnant as assessed by a urine pregnancy test at Screening (V1) or individual's that intend to become pregnant during the study or are breastfeeding; 2. Treatment with another investigational drug or other intervention within 30 days of Screening (V1); 3. Have initiated psychotherapy in the preceding 12 weeks prior to Screening (V1); 4. Have a DSM-5 diagnosis of substance use disorder (use of tobacco is permitted) within the preceding 6 months; 5. Have active suicidal ideation with intent and plan as determined by item 3 of the HamD-17; 6. Any DSM-5 lifetime diagnosis of a schizophrenia-spectrum disorder; obsessive-compulsive disorder, psychotic disorder (unless substance induced or due to a medical condition), bipolar I or II disorder, paranoid personality disorder, borderline personality disorder, or neurocognitive disorder as determined by medical history and the SCID-5 clinical interview; 7. Any first-degree relative with a diagnosis of schizophrenia-spectrum disorder; psychotic disorder (unless substance-induced or due to a medical condition); or bipolar I disorder as determined by the family medical history form and discussions with the participant; 8. Presence of a relative or absolute contraindication to psilocybin, including a drug allergy, recent stroke history, uncontrolled hypertension, low or labile blood pressure, recent myocardial infarction, cardiac arrhythmic, severe coronary artery disease, or moderate to severe renal or hepatic impairment. 9. Presence of baseline prolonged QTc or Torsade de Pointes as measured by the ECG or a history of long QTc syndrome or related risk factors; 10. History of allergy or contraindication to risperidone 11. Current or past traumatic brain injury or other neurological/neurodegenerative disorder 12. Unable or unwilling to undergo PET or MRI scanning (e.g. claustrophobia, pacemaker); 13. Blood disorders, disorders of coagulation, or ongoing use of anticoagulant medication 14. Any disability that may prevent the participant from completing study requirements (e.g., non-correctable clinically significant sensory impairment such as not hearing well enough to communicate with study personnel during scans, or physical disability that does not allow them to lie still on the scanner bed for 1-2 hours); 15. Participant exceeds the annual or lifetime amount of radiation 16. Any other clinically significant physical illness including chronic infectious diseases or any other major concurrent illness that, in the opinion of the investigator, may interfere with the interpretation of the study results or constitute a health risk for the participant if they take part in the study.

Inclusion Criteria: * Healthy adults aged 19 to 54 years * BMI measurement result is 18.0 kg/m2 to 30 kg/m2 * Written informed consent * Other inclusion criteria, as defined in the protocol Exclusion Criteria: * who has taken drug metabolism enzyme induction and inhibitory drugs, such as barbitale drugs, within 30 days prior to the start of the trial (Period 1 administration) * Other exclusive criteria, as defined in the protocol

Inclusion Criteria: * Age ≥18yrs； * Diagnosed as Type 2 Diabetes; * Had been on a stable hypoglycemic regimen for at least 30 days prior to screening； * HbA1c between 7.5% and 11.0% (both upper and lower limits included) in the 90 days prior to screening; * Fasting C-peptide ≥1.0ng/ml in the 90 days prior to screening; * Be willing to accept and adhere to LGI steamed bread as a staple food for at least 14 days Exclusion Criteria: * Diagnosed with type 1 diabetes, or secondary diabetes; * Have clinically significant liver disease, moderate/severe kidney injury, or end-stage renal disease; * Has unstable CV disorders, including heart failure (NYHA) class III or IV), intractable angina, uncontrolled arrhythmias, and severe uncontrolled hypertension (systolic blood pressure ≥180mmHg, or diastolic blood pressure ≥105mmHg); * An Acute Coronary Syndrome event (ACS) occurred within the 6 months prior to randomization

Inclusion Criteria: 1. Age ≥ 18 years old; 2. Pathological or histopathological confirmed HER2 positive cases cannot be surgically advanced or metastasized Patients with sexual breast cancer (HER2 positive is defined as: standard immunohistochemistry (IHC) Detected as 3+or ISH positive); 3. There is a traceable medical history record during the treatment period; 4. Voluntarily participate in this study, sign informed consent, have good compliance, and are willing to cooperate Follow up. Exclusion Criteria: 1. Failure to sign informed consent form; 2. Previous history of other malignant tumors, but cured skin basal cell carcinoma and cervical cancer Excluding cancer; 3. Difficulty in swallowing, chronic diarrhea, and intestinal obstruction, which can affect medication administration and absorption Various factors; 4. Pregnant or lactating women, and women of childbearing age who cannot achieve optimal contraception; 5. Any other circumstances in which the researcher deems the patient unsuitable to participate in this study.

Inclusion Criteria: * Provision of signed and dated consent form * Ages 18-75 * Diagnosis of PAH * On stable treatment for PAH for one month prior to enrollment * Able to swallow capsules * Able to provide blood sample and fecal sample * Stated willingness to comply with all study procedures and availability for the duration of trial to follow-up by telephone, in-person, email, and/or video visits or correspondence. Exclusion Criteria: * Dysphagia to pills * Clinically active inflammatory bowel disease * Pregnancy or breastfeeding. A pregnancy test will be obtained from females of child- bearing potential at the screening visit or day 1 (prior to the receipt of MTT). Patients with a positive pregnancy test will be excluded. A negative result will be required for subjects who are females of child-bearing potential to receive MTT. Patients will be counseled to avoid pregnancy which is the standard of care for patients with PAH. * Life expectancy of \< 6 months * Presence of ileostomy or colostomy * Patients on immunosuppressants (calcineurin inhibitors, prednisone ≥ 20 mg/day, methotrexate, azathioprine, immunosuppressive biologics, JAK inhibitors). * Patients with neutropenia (an absolute neutrophil count \< 0.5 x 10 9 cells/L) obtained on a complete blood count with differential at screening * History of solid organ or bone marrow transplant * Anticipated recurrent antibiotic use (patients with frequent urinary tract infections or sinusitis) * History of severe anaphylactic food allergy * History of celiac disease * Patients receiving cancer chemotherapy, immunotherapy, or radiation * Patients with severe Irritable bowel syndrome (IBS) defined by an IBS score \>250

Inclusion Criteria: * Subjects aged 18 years or older but younger than 80 years * Individuals who voluntarily decide to participate in this clinical trial and provide written consent to the information and consent form * Individuals willing to comply with the clinical trial protocol Exclusion Criteria: * Subjects who do not consent to the study * Obese individuals with a Body Mass Index (BMI) of 30 or higher (concerns about measurement errors as the standard 24-hour ambulatory blood pressure monitor cuff may not fit the arm properly) * Patients or volunteers who are pregnant * Patients or volunteers with underlying heart diseases: those with a history of hospitalization for heart failure, valvular disease, or myocardial infarction * Patients or volunteers diagnosed with atrial fibrillation on a 12-lead electrocardiogram (ECG) within the past 6 months * Patients or volunteers with end-stage renal disease (undergoing dialysis) * Patients or volunteers unable to perform repeated exercises required for the study * Patients or volunteers with a systolic blood pressure (SBP) exceeding 160 millimeters of mercury (mmHg) * Patients or volunteers with a systolic blood pressure (SBP) exceeding 160 millimeters of mercury (mmHg) and/or a diastolic blood pressure (DBP) exceeding 100 millimeters of mercury (mmHg) (for exercise tests)

Inclusion Criteria: * U.S. military veteran between 18-65 years old * negative pregnancy test on MRI scan days * score greater than or equal to 10 on the Suicide Rumination Scale * clinically stabilized on psychotropic medications * engaged in mental health care treatment * able to provide written, informed consent Exclusion Criteria: * no major medical or neurological disorders that could interfere with treatment * moderate or severe traumatic brain injury * current imminent suicide risk, as determined through psychiatric interview, responses to C-SSRS, and clinical judgment of the assessor * any current psychotic disorder * MRI contraindications * any substance use disorder for substances other than cannabis or alcohol (mild alcohol or cannabis use disorder does not exclude participants but moderate or severe alcohol or cannabis substance use disorder is disqualifying) * pregnant or trying to become pregnant

Inclusion criteria: 1. SCI of any level or severity 2. 18 years of age or older 3. scores suggesting mild - moderately severe depression on the PHQ-9 (5 - 19) 4. stable dose of depression medications Exclusion criteria: 1. Prone to autonomic dysreflexia 2. Severe depression as assessed by PHQ-9 (≥20) 3. Suicidal ideation 4. presence of cardiovascular disease 5. pacemaker or other implanted electrical device (e.g. cochlear implant, implanted vagus nerve stimulator, cardiac pacemaker) 6. people with cerebral shunts 7. people with epilepsy 8. people who pregnant or attempting to become pregnant.

Inclusion Criteria: * Adults aged 40 to 75 years old, previously diagnosed with resistant hypertension, and on stable medication for at least 6 months. Exclusion Criteria: * People with secondary hypertension, heart failure, peripheral artery disease, atrial fibrillation, chronic obstructive pulmonary disease or renal failure; people with a cerebro-cardiovascular event in the previous 3 months; people with changes in pharmacological therapy in the previous 6 months; trained people (with regular participation (≥ 2x/week) in exercise training programs in the previous 3 months); people who have any contraindication to exercise; people with neurological and/ or orthopaedic conditions that will interfere with their participation in exercise, such as Parkinson's disease or knee osteoarthritis. Participants with low score (\<6) on the MMAS-8 will also be excluded.

Inclusion Criteria: * Aged 18-34 * From groups other than non-Hispanic White * Enrolled in services at the partnering clinic site Exclusion Criteria: * Cognitive impairments (i.e., young adult cannot understand consent process) * Unable to comprehend and speak English

Inclusion Criteria: * Working in a nursing home * Not being allergic to flowers and plants * Willingness to work * To be open to communication and cooperation, * Scoring 8 points or more on the stress sub-dimension of the DASS measurement tool Exclusion Criteria: * Those with musculoskeletal disorders * Those who use antipsychotic drugs

Inclusion Criteria: * Age from 18 to 50 years old * Singleton pregnancies between 20 and 41 weeks of gestation * Preeclampsia / normal pregnancy Exclusion Criteria: * Age \< 18 years old * Infectious disease: HIV, HBV or HCV * Multiple pregnancies * refusal to participate in the protocol * Lack of social security cover

Inclusion Criteria: * Individuals with a diagnosis of Type 2 Diabetes Mellitus who are enrolled in Teamlets in NHGP * Age between 21 to 64 years old * HbA1c level of more than 8% in the last 6 months Exclusion Criteria: * History of acute coronary syndrome in the past 3 months * History of stroke or transient ischaemic attacks in the past 3 months * History of end stage organ failure (liver cirrhosis, cardiac failure, latest eGFR \<30 mL/min/1.73m2 in the last 6 months) * Cancer requiring treatment in the past 5 years. * Active psychiatrist follow up * Social issues that are significant enough for follow-up or referral with a medical social worker within the last 12 months * Women who are pregnant or breastfeeding * Patients who are enrolled in other current diabetes-related interventional studies * Inability to provide written consent for the study protocol and able to commit to the study duration.

Inclusion Criteria: * Adults age 18 or greater with diagnosis of hypertension AND blood pressure (BP) greater than or equal to 140/90 OR currently taking antihypertensive medication. * Ability to provide informed consent Exclusion Criteria: * Pregnancy * Severe comorbid condition(s) with life expectancy less than 1 year

Inclusion Criteria: 1. Age more than 18 years old 2. Diagnosed as herpes zoster neuralgia 3. Signing informed consent Exclusion Criteria: 1. Unable to complete the scale assessment 2. History of mental illness

Inclusion Criteria: * Women ≥ 18 years of age * Histological confirmation of ER+, HER2- breast cancer, newly diagnosed and tissue available for central confirmation of Ki-67 measurement. Subjects are eligible if they have a Ki-67 of ≥10%. Ki-67 will be repeated for patients who have had this done externally. * Scheduled for definitive breast surgery * Detectable disease as defined by mammography, breast ultrasound of greater than 5mm in size. * NOTE: Tumor lesions in a previously irradiated area are not considered measurable disease; Disease that is measurable by physical examination only is not eligible * Post menopausal as defined by: * Self-reported last menstrual period greater than 12 months, or * Bilateral oophorectomy, or * Follicle stimulating hormone (FSH) \>20 mIU/mL, and estradiol level ≤ 20 pg/mL * Not taking aromatase inhibitor or a selective estrogen receptor modifier * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2 obtained ≤ 90 days prior to registration * Platelet count ≥ 100,000/mm\^3 (obtained ≤ 90 days prior to registration) * Absolute neutrophil count (ANC) ≥ 1,000/mm\^3 (obtained ≤ 90 days prior to registration) * Hemoglobin ≥ 11 g/dL (obtained ≤ 90 days prior to registration) * Serum transaminase \[alanine aminotransferase (ALT) or aspartate aminotransferase (AST)\] ≤ 1.2 x upper limit of normal (ULN) (obtained ≤ 90 days prior to registration) * Alkaline phosphatase ≤ 1.2 x ULN (obtained ≤ 90 days prior to registration) * Serum creatinine ≤ 1.2 x ULN (obtained ≤ 90 days prior to registration) * Provide written informed consent * Ability to complete the Symptom Experience Diary by themselves or with assistance Exclusion Criteria: * Ki-67 of \<10% * Current use of any medicinal mushrooms * Patient with locally advanced cancer who will require neoadjuvant therapy or metastatic cancer * Currently on systemic chemotherapy * Concurrent endocrine therapy (selective estrogen receptor modifiers or aromatase inhibitors) * Allergy to mushrooms * Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens * Immunocompromised patients * Patients known to be HIV positive and currently receiving antiretroviral therapy. * NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial * Uncontrolled intercurrent illness including, but not limited to: * Ongoing or active infection * Symptomatic congestive heart failure * Unstable angina pectoris * Cardiac arrhythmia * Or psychiatric illness/social situations that would limit compliance with study requirements * Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm * Other active malignancy 3 years prior to registration * EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix * NOTE: If there is a history of prior malignancy, they must not be receiving chemotherapy treatment for their cancer

Inclusion Criteria: * being a war-affected young adult (referred to as the index participant) previously interviewed at one or more waves of the Longitudinal Study of War Affected Youth (LSWAY) who still resides in Sierra Leone * being a cohabitating intimate partner of the index participant; or (c) being a cohabitating biological child (aged 7-24) of the index participant. Exclusion criteria are (a) not being sampled in a prior LSWAY wave * being a cohabitating biological child (aged 7-24) of the index participant Exclusion Criteria: * not being sampled in a prior LSWAY wave * not being a biological child or intimate partner of the index cohort participant * being in acute crisis (active suicidality or psychosis)